MNG1046
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.468
- IL6_JAK_STAT3_SIGNALING+0.379
- INTERFERON_GAMMA_RESPONSE+0.377
- INTERFERON_ALPHA_RESPONSE+0.356
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.337
- PI3K_AKT_MTOR_SIGNALING+0.286
- UNFOLDED_PROTEIN_RESPONSE+0.271
- TGF_BETA_SIGNALING+0.265
- ADIPOGENESIS+0.238
- INFLAMMATORY_RESPONSE+0.238
Top 10 suppressed
- SPERMATOGENESIS-0.273
- TNFA_SIGNALING_VIA_NFKB-0.251
- PANCREAS_BETA_CELLS-0.243
- ESTROGEN_RESPONSE_EARLY-0.161
- E2F_TARGETS-0.144
- ESTROGEN_RESPONSE_LATE-0.141
- G2M_CHECKPOINT-0.140
- KRAS_SIGNALING_DN-0.129
- UV_RESPONSE_UP-0.123
- NOTCH_SIGNALING-0.086
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.468 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.379 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.377 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.356 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.337 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.286 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.271 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.265 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.238 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.238 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.204 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.204 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.202 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.188 | Idelalisib | — uncovered |
| COMPLEMENT | 0.178 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.175 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.170 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.155 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.144 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.134 | Inavolisib | — uncovered |